Arctic Bioscience (ABS.OL) reported a Q1 2025 topline of NOK 9.35 million, marking a 8.7% year-over-year revenue increase but a material sequential decline of 31.3% versus the prior quarter. Gross profit totaled NOK 3.61 million, yielding a gross margin of 38.6%. The quarter delivered an EBITDA of negative NOK 7.37 million and a net loss of NOK 9.47 million, with basic earnings per share of NOK -0.35. These results underscore the company’s current development-stage profile, where substantial R&D and related SG&A expenses weigh on near-term profitability despite a modest revenue base.
The company continues to allocate significant resources toward its psoriasis program (HRO350) and related development activities, alongside the nutraceuticals business under the ROMEGA brand. R&D expense for QQ1 2025 was NOK 0.57 million, while selling, general and administrative costs stood at NOK 5.35 million, and other operating charges totaled NOK 5.78 million. The earnings trajectory remains contingent on downstream milestones for HRO350, potential licensing or collaboration agreements, and any acceleration in nutraceuticals-based revenue. Management commentary for QQ1 2025 is not provided in the supplied data, limiting quantitative guidance; nonetheless, investors should monitor clinical readouts, strategic BD activity, and financing runway.
From a market context, Arctic’s gross margin of 38.6% lags some peers in the listed biotech/biopharma space, while the aggressive cost structure keeps operating and net margins deeply negative. The near-term investment case hinges on: (1) advancing HRO350 through development milestones or partnering, (2) scaling the ROMEGA nutritionals business, and (3) securing balanced financing to sustain the research pipeline. Given the lack of explicit forward guidance, the investment thesis remains high-risk and high-variance, with potential upside if pivotal clinical or commercial milestones are achieved.